Risk of Hepatitis B Virus Reactivation in Patients With Inflammatory Arthritis Receiving Disease-Modifying Antirheumatic Drugs: A Systematic Review and Meta-Analysis.

Tzu-Chieh LinKazuki YoshidaSara K TedeschiMirhelen Mendes de AbreuNikroo HashemiDaniel H Solomon

Published in: Arthritis care & research (2018)

We found that the HBV reactivation rate in inflammatory arthritis patients receiving DMARDs was low in resolved patients and moderate in patients with chronic HBV infection. Further, lower rates were observed in patients with chronic HBV infection who were using antiviral prophylaxis.

Keyphrases

hepatitis b virus
rheumatoid arthritis
liver failure
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
oxidative stress
rheumatoid arthritis patients
prognostic factors
disease activity